BACKGROUND: Ruta graveolens is a medicinal herb that has been used for centuries against various ailments. This study examined the anticancer properties of the herb using cancer cell lines. MATERIALS AND METHODS: Methanolic extract of R. graveolens was tested on colon, breast and prostate cancer cells. Viability, cell cycle profiles, clonogenicity and capase activation were measured. Induction and subcellular localizations of p53, 53BP1 and γ-H2AX proteins were examined. RESULTS: The extract dose-dependently decreased the viability and the clonogenicity of treated cells and induced G₂/M arrest, aberrant mitoses, and caspase-3 activation. It also induced the p53 pathway and focal concentration of the DNA damage response proteins 53BP1 and γ-H2AX. Moreover, the levels of phospho-Akt and cyclin B1 were reduced by treatment, whereas only cyclin B1 was reduced in normal dermal fibroblasts. CONCLUSION: R. graveolens extract contains bioactive compounds which, independently of known photoactivatable mechanisms, potently inhibit cancer cell proliferation and survival through multiple targets.
BACKGROUND:Ruta graveolens is a medicinal herb that has been used for centuries against various ailments. This study examined the anticancer properties of the herb using cancer cell lines. MATERIALS AND METHODS:Methanolic extract of R. graveolens was tested on colon, breast and prostate cancer cells. Viability, cell cycle profiles, clonogenicity and capase activation were measured. Induction and subcellular localizations of p53, 53BP1 and γ-H2AX proteins were examined. RESULTS: The extract dose-dependently decreased the viability and the clonogenicity of treated cells and induced G₂/M arrest, aberrant mitoses, and caspase-3 activation. It also induced the p53 pathway and focal concentration of the DNA damage response proteins 53BP1 and γ-H2AX. Moreover, the levels of phospho-Akt and cyclin B1 were reduced by treatment, whereas only cyclin B1 was reduced in normal dermal fibroblasts. CONCLUSION:R. graveolens extract contains bioactive compounds which, independently of known photoactivatable mechanisms, potently inhibit cancer cell proliferation and survival through multiple targets.
Authors: Salvador A Arias-Santiago; María A Fernández-Pugnaire; Francisco M Almazán-Fernández; Cristina Serrano-Falcón; Salvio Serrano-Ortega Journal: Rheumatology (Oxford) Date: 2009-08-11 Impact factor: 7.580
Authors: M L Panno; F Giordano; M G Palma; V Bartella; V Rago; M Maggiolini; D Sisci; M Lanzino; F De Amicis; S Andò Journal: Curr Cancer Drug Targets Date: 2009-06 Impact factor: 3.428
Authors: Anna Oliva; Kumudini M Meepagala; David E Wedge; Dewayne Harries; Amber L Hale; Giovanni Aliotta; Stephen O Duke Journal: J Agric Food Chem Date: 2003-02-12 Impact factor: 5.279
Authors: José Manuel Bravo-San Pedro; Oliver Kepp; Allan Sauvat; Santiago Rello-Varona; Guido Kroemer; Laura Senovilla Journal: Methods Mol Biol Date: 2021
Authors: Iris R Bell; Barbara Sarter; Mary Koithan; Prasanta Banerji; Pratip Banerji; Shamini Jain; John Ives Journal: Glob Adv Health Med Date: 2014-01
Authors: C C Estanislao Gómez; A Aquino Carreño; D G Pérez Ishiwara; E San Martín Martínez; J Morales López; N Pérez Hernández; M C Gómez García Journal: BMC Complement Altern Med Date: 2016-08-05 Impact factor: 3.659